Jumia Technologies AG
Change company Symbol lookup
Select an option...
JMIA Jumia Technologies AG
BVH Bluegreen Vacations Holding Corp
GTY Getty Realty Corp
SWX Southwest Gas Holdings Inc
EFR Eaton Vance Senior Floating-Rate Trust
FSRXW FinServ Acquisition II Equity Warrant Exp 17 Feb 2026 *W EXP 02/17/2026
PTRA Proterra Inc
IH Ihuman Inc
LMT Lockheed Martin Corp
GBRGU Goldenbridge Acquisition Ltd
Go

Consumer Discretionary : Internet & Direct Marketing Retail |
Based in Germany
Company profile

Jumia Technologies AG is a Germany-based e-commerce platform provider. The Company’s platform consist of sellers with consumers, its logistics service, which enables the shipment and delivery of packages from sellers to consumers, and its payment service, which facilitates transactions among participants active on the Company’s platform. The Company’s marketplace is consists of a range of sellers that offer goods in a wide range of categories, such as fashion and apparel, smartphones, home and living, consumer packaged goods, beauty and perfumes and other electronics. The Company also provide consumers with access to a various services, such as restaurant food delivery, hotel and flight booking, classified advertising and airtime recharge.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$13.27
Day's Change
2.20 (19.89%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.61
Day's Low
12.39
Volume
(Heavy Day)

Today's volume of 8,896,392 shares is on pace to be much greater than JMIA's 10-day average volume of 5,155,949 shares.

8,896,392

Sesen Class Action Reminder

6:27 pm ET October 14, 2021 (Newsfile) Print

New York, New York--(Newsfile Corp. - October 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sesen Bio, Inc. ("Sesen" or the "Company") (NASDAQ: SESN) and reminds investors of the October 18, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in Sesen stock or options between December 21, 2020 and August 17, 2021 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/SESN.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6455/99751_90ea2f80945fb92b_001.jpg



There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) that Sesen Bio's clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) that three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum; (4) that Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 18, 2021, before the market opened, STAT published an article entitled "Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show." Citing "hundreds of pages of internal documents" and "three people familiar with the matter," the article detailed that the clinical trial for Vicineum was "marked by thousands of violations of study rules, damning investigator conduct, and worrying signs of toxicity the company did not publicly disclose."

The STAT article further stated that Vicineum had led to "worrisome side effects," including "a serious risk for fatal, drug-induced liver injury."

On this news, the Company's share price fell $0.20, or 13%, to close at $1.31 per share on August 18, 2021, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Sesen's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99751

comtex tracking

COMTEX_395220692/2523/2021-10-14T18:27:58

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.